The Optimization of Mycoplasm Pneumonia Antibiotic Therapy

Mycoplasma Pneumonia Clinical Trial

Official title: The Optimization of Mycoplasm Pneumonia Antibiotic Therapy: Multi-centre, Prospective, Randomized Controlled Study

Status Completed

Clinical Trial Summary

Mycoplasma pneumoniae, an important pathogen of community acquired pneumonia,are becoming more and more resistant to macrolide. The study aim is to optimize anti-infection therapy.

Clinical Trial Description

Mycoplasma pneumoniae was one of important atypical pathogens of community acquired pneumonia. As lack of cell wall, β-lactam medicines were invalid, however, macrolides, tetracyclines and quinolones were effective. But from 2001, many countries reported macrolide- resistant Mycoplasma pneumoniae. Typically, erythromycin was first-line antibiotic medicine. With the resistance increasing, Mycoplasm pneumonia treatment will become more and more difficult. Thus, optimization of Mycoplasm pneumonia antibiotic therapy is very important. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Mycoplasma Infections
• Mycoplasma Pneumonia
• Pleuropneumonia
• Pneumonia
• Pneumonia, Mycoplasma

• NCT number: NCT01259141
• Study type: Interventional
• Source: Capital Medical University
• Status: Completed
• Phase: N/A
• Start date: October 2010
• Completion date: December 2014